BRPI0512832A - composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para usar um composto - Google Patents

composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para usar um composto

Info

Publication number
BRPI0512832A
BRPI0512832A BRPI0512832-3A BRPI0512832A BRPI0512832A BR PI0512832 A BRPI0512832 A BR PI0512832A BR PI0512832 A BRPI0512832 A BR PI0512832A BR PI0512832 A BRPI0512832 A BR PI0512832A
Authority
BR
Brazil
Prior art keywords
compound
stereoisomer
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
Prior art date
Application number
BRPI0512832-3A
Other languages
English (en)
Inventor
Jeffrey M Bergman
Paul J Coleman
Mark E Fraley
Robert M Garbaccio
George D Hartman
Chunze Li
Lou Anne Neilson
Christy M Olson
Edward S Tasber
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BRPI0512832A publication Critical patent/BRPI0512832A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

COMPOSTO OU UM SAL OU ESTEREOISÈMERO FARMACEUTICAMENTE ACEITáVEL DO MESMO, COMPOSIçãO FARMACêUTICA, E, MéTODO PARA USAR UM COMPOSTO. A presente invenção se refere a pirazóis tricíclicos de acordo com Fórmula (I) que são úteis para tratar doenças de proliferação celular, para tratar distúrbios associados com atividade de cinesina KSP, e para inibir cinesina KSP. A invenção também se refere a composições que compreendem estes compostos, e métodos de usar elas para tratar câncer em mamíferos.
BRPI0512832-3A 2004-07-01 2005-06-27 composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para usar um composto BRPI0512832A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58480804P 2004-07-01 2004-07-01
US60090104P 2004-08-12 2004-08-12
PCT/US2005/022730 WO2006007491A1 (en) 2004-07-01 2005-06-27 Mitotic kinesin inhibitors

Publications (1)

Publication Number Publication Date
BRPI0512832A true BRPI0512832A (pt) 2008-04-08

Family

ID=35149059

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512832-3A BRPI0512832A (pt) 2004-07-01 2005-06-27 composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para usar um composto

Country Status (15)

Country Link
US (1) US7632833B2 (pt)
EP (1) EP1765830B1 (pt)
JP (1) JP2008505085A (pt)
KR (1) KR20070039885A (pt)
CN (1) CN1980938B (pt)
AT (1) ATE482218T1 (pt)
AU (1) AU2005262373B2 (pt)
BR (1) BRPI0512832A (pt)
CA (1) CA2571807A1 (pt)
DE (1) DE602005023730D1 (pt)
IL (1) IL180328A0 (pt)
MX (1) MXPA06015275A (pt)
NO (1) NO20070589L (pt)
RU (1) RU2007103816A (pt)
WO (1) WO2006007491A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8796460B2 (en) 2007-10-19 2014-08-05 Mercky Sharp & Dohme Corp. Compounds for inhibiting KSP kinesin activity
RU2654068C1 (ru) * 2009-09-28 2018-05-16 Ф.Хоффманн-Ля Рош Аг Бензоксазепиновые ингибиторы pi3 и способы применения
US20140087309A1 (en) * 2011-04-01 2014-03-27 The Research Foundation Of State University Of New York Olefin-triggered acid amplifiers
KR20140033027A (ko) * 2011-04-01 2014-03-17 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 안정화된 산 증폭제
WO2013123081A2 (en) 2012-02-14 2013-08-22 Children's Hospital Medical Center Use of small molecule inhibitors targeting the interaction between rac gtpase and p67 (phox)
JP6434496B2 (ja) * 2013-04-22 2018-12-05 アッヴィ・インコーポレイテッド チアゾールおよびその使用
US10323042B2 (en) * 2016-02-23 2019-06-18 Pfizer Inc. 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0437455A1 (en) 1988-09-22 1991-07-24 E.I. Du Pont De Nemours And Company Substituted indazole arthropodicides
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
US5719147A (en) 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
ATE160345T1 (de) 1993-01-15 1997-12-15 Searle & Co 3,4-diarylthiophene und analoga davon, sowie deren verwendung als entzündungshemmende mittel
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
GB9602877D0 (en) 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5393790A (en) 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6020343A (en) 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
BR9708574A (pt) 1996-04-12 1999-08-03 Searle & Co Derivados benzeno sulfonamida substituídos como pródrogas de inibidores cox-2
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
DE19805117A1 (de) 1998-02-09 1999-08-12 Bayer Ag Neue Oxazolidinone mit azolhaltigen Tricyclen
DE19905278A1 (de) 1999-02-09 2000-08-10 Bayer Ag Oxazolidinone und ihre Verwendung als antibakterielle Mittel
ATE372341T1 (de) 2001-12-06 2007-09-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
WO2003079973A2 (en) 2002-03-08 2003-10-02 Merck & Co., Inc. Mitotic kinesin inhibitors

Also Published As

Publication number Publication date
JP2008505085A (ja) 2008-02-21
US7632833B2 (en) 2009-12-15
EP1765830B1 (en) 2010-09-22
CN1980938B (zh) 2010-11-03
CA2571807A1 (en) 2006-01-19
EP1765830A1 (en) 2007-03-28
MXPA06015275A (es) 2007-03-15
RU2007103816A (ru) 2008-08-10
NO20070589L (no) 2007-03-22
ATE482218T1 (de) 2010-10-15
AU2005262373A1 (en) 2006-01-19
US20080287414A1 (en) 2008-11-20
DE602005023730D1 (de) 2010-11-04
AU2005262373B2 (en) 2011-03-17
KR20070039885A (ko) 2007-04-13
CN1980938A (zh) 2007-06-13
IL180328A0 (en) 2007-07-04
WO2006007491A1 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
ATE446094T1 (de) Mitotische kinesin-hemmer
ATE448207T1 (de) Mitotische kinesin-hemmer
EP1515949A4 (en) INHIBITORS OF MITOTIC KINESINE
DK1664026T3 (da) Inhibitorer af mitotisk kinesin
ATE424388T1 (de) Mitotische kinesinhemmer
ATE447577T1 (de) Mitotische kinesin-hemmer
EP1463733A4 (en) INHIBITORS OF MITOTIC KINESINE
WO2005017190A3 (en) Mitotic kinesin inhibitors
WO2005018547A3 (en) Mitotic kinesin inhibitors
WO2005065183A3 (en) Mitotic kinesin inhibitors
WO2005060654A3 (en) Mitotic kinesin inhibitors
WO2006068933A3 (en) Mitotic kinesin inhibitors
WO2006101761A3 (en) Mitotic kinesin inhibitors
NO20070589L (no) Mitotiske kinesin-inhibitorer.
WO2006086358A3 (en) Mitotic kinesin inhibitors
ATE419249T1 (de) Inhibitoren von mitotischem kinesin
WO2006031348A3 (en) Mitotic kinesin inhibitors
WO2006078598A3 (en) Mitotic kinesin inhibitors
EP1635641A4 (en) INHIBITORS OF MITOTIC KINESINE
WO2006007496A3 (en) Mitotic kinesin inhibitors
WO2006007501A3 (en) Mitotic kinesin inhibitors
WO2006023440A3 (en) Mitotic kinesin inhibitors
WO2004087050A3 (en) Mitotic kinesin inhibitors
WO2005092011A3 (en) Mitotic kinesin inhibitors
WO2006007497A3 (en) Prodrugs of mitotic kinesin inhibitors

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]